gbpoietin
Generic Name
gbpoietin-5000-iu-injection
Manufacturer
Acme Pharmaceuticals
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| gbpoietin 5000 iu injection | ৳ 2,990.19 | N/A |
Description
Overview of the medicine
Epoetin alfa is a recombinant human erythropoietin, used to treat anemia by stimulating red blood cell production. It is a glycoprotein that acts like the natural hormone erythropoietin produced by the kidneys.
Uses & Indications
Dosage
Adults
Dosage varies based on indication, route, and patient response. For CKD, typically 50-100 IU/kg three times weekly (IV or SC), adjusted to maintain target hemoglobin levels (10-11 g/dL). For cancer chemotherapy, 150-300 IU/kg once weekly or 40,000-60,000 IU once weekly (SC).
Elderly
Similar to adult dosage, but close monitoring required due to potential comorbidities and increased sensitivity.
Renal_impairment
Specific dosage guidelines for CKD patients are provided; no additional adjustment beyond these standard CKD dosing recommendations.
How to Take
gbpoietin can be administered either intravenously (IV) or subcutaneously (SC). The route of administration depends on the patient's condition and the indication. Do not shake the vial/syringe vigorously. Administer slowly.
Mechanism of Action
Epoetin alfa stimulates erythropoiesis by binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow, leading to red blood cell proliferation and differentiation, ultimately increasing red blood cell mass.
Pharmacokinetics
Onset
Significant increase in reticulocytes within 10 days, with a rise in hemoglobin levels typically seen in 2-6 weeks.
Excretion
Only a small fraction is excreted renally; larger molecules like epoetin are usually catabolized.
Half life
IV: 4-13 hours. SC: 13-24 hours.
Absorption
Subcutaneous absorption is slow and incomplete (bioavailability 30-40%). Intravenous administration results in rapid distribution.
Metabolism
Primarily degraded by receptor-mediated endocytosis in erythroid progenitor cells; partially metabolized in the liver.
Side Effects
Contraindications
- •Uncontrolled hypertension.
- •Known hypersensitivity to mammalian cell-derived products or any component of the formulation.
- •Pure red cell aplasia (PRCA) developed after treatment with any erythropoietin protein.
- •Patients with serious cardiovascular events, including stroke or myocardial infarction, within the last month (for perioperative use).
Drug Interactions
Ciclosporin
Epoetin may increase ciclosporin blood levels, requiring close monitoring and potential dosage adjustment of ciclosporin.
Iron supplements
Often needed concurrently, as iron stores may become depleted due to increased erythropoiesis. Monitor iron status and supplement as needed.
Storage
Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Do not shake.
Overdose
Overdose can lead to polycythemia (excessive red blood cells) with associated complications like increased blood viscosity, thrombotic events, and hypertension. Management involves phlebotomy to reduce hematocrit and symptomatic supportive care.
Pregnancy & Lactation
Pregnancy Category C. Use during pregnancy only if clearly needed and potential benefits outweigh risks. Caution advised during lactation as it is unknown if epoetin is excreted in human milk; weigh benefits against potential risks to the infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Generally 24 to 36 months when stored under recommended conditions.
Availability
Hospitals, Clinics, Pharmacies
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA, DGDA)
Patent Status
Patent expired for original compound, biosimilars available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
